

Special Issue

Graft-Versus-Host Disease (GVHD) After Hematopoietic Cell Transplantation (HCT)

Message from the Guest Editor

Although hematopoietic cell transplantation (HCT) is potentially curative for hematological malignancies, it can often lead to several complications that can be life threatening. One of the major causes of mortality and morbidity after HCT is graft-versus-host disease (GVHD). Despite the significant advances in GvHD prophylaxis, the incidence of GVHD remains high with around 10–15% of cases being severe. High-dose corticosteroids remains the cornerstone for GVHD therapy. The response rates have been disappointing, and steroid-refractory GvHD prognosis remains dismal. This Special Issue welcomes original research articles and reviews. Research areas of interest include (but are not limited to) the following:

- Incidence of GVHD;
- Risk factors of GVHD;
- Treatment outcomes of GVHD;
- Complications;
- Biomarkers for GVHD.

I look forward to receiving your contributions.

Guest Editor

Dr. Monzr M. Al-Malki

Department of Hematology and Hematopoietic Cell Transplantation,
City of Hope, Duarte, CA, USA

Deadline for manuscript submissions

closed (30 September 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/217724

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)